BioStem Technologies Files S-1 Registration for U.S. IPO
BioStem Technologies, Inc. (File No. 0001658678) filed its Form S-1 registration statement with the SEC on October 2, 2026, initiating its U.S. IPO process on Nasdaq or NYSE. The 11-MB filing marks the formal start of financial disclosure and regulatory review.
51CFO view：CFOs of biotech IPO candidates must lead S-1 financial section drafting: R&D expense capitalization policy, revenue recognition for clinical-stage collaborations, ASC 730/985 compliance, and SOX 404 readiness. FDA-regulated financial reporting experience is non-negotiable.
BioStem Technologies, Inc. (File No. 0001658678) filed its Form S-1 registration statement with the SEC on October 2, 2026, initiating its U.S. IPO process on Nasdaq or NYSE. The 11-MB filing marks the formal start of financial disclosure and regulatory review.
Source：SEC EDGAR · S-1 招股书备案